COL Immunotherapy Before Radiochimio + Ipilimumab
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cervix Cancer
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
The aim of COLIBRI is to evaluate the evolution of the CD8+/FOXP3+ ratio of lymphocytes in pre- versus post-treatment biopsies in patients treated with a combination of Nivolumab and Ipilimumab in a pilot study, just before starting standard RT-CT. The study will also assess tolerability, Objective ...
The aim of COLIBRI is to evaluate the evolution of the CD8+/FOXP3+ ratio of lymphocytes in pre- versus post-treatment biopsies in patients treated with a combination of Nivolumab and Ipilimumab in a pilot study, just before starting standard RT-CT. The study will also assess tolerability, Objective Response Rate, clinical activity and biological (dynamic) changes of the immune micro environment
Tracking Information
- NCT #
- NCT04256213
- Collaborators
- Bristol-Myers Squibb
- Investigators
- Principal Investigator: Isabelle RAY-COQUARD, MD, PhD Centre Leon Berard
Get Well Soon